Market Trends of Surrogacy Industry
The IVF with Intracytoplasmic Sperm Injection Segment is Expected to Witness Significant Growth Over the Forecast Period
Intracytoplasmic sperm injection (ICSI) is an in-vitro fertilization technique during which a single sperm can be injected directly into the egg for fertilization.
The in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) segment is expected to grow over the forecast period, owing to factors such as the rising number of infertility cases among the population. Factors such as smoking, taking antibiotics, depression, and other health conditions, growing demand for surrogacy procedures, and the increasing awareness among the population regarding assisted reproductive technology (ART) procedures are also expected to facilitate market growth.
In addition, the emerging advanced technologies used for fertility procedures and growing government initiatives are also expected to fuel IVF with intracytoplasmic sperm injection procedures, which, in turn, is expected to augment the segment growth over the forecast period.
The use of ICSI has increased globally, mainly in couples with non-male factors. IVF with ICSI facilitates the selection of sperm with good morphological characteristics, increases the chances of fertilization of eggs and the quality of potentially usable embryos, and avoids fertilization failure rates. Such advantages offered by ICSI make it a primary choice for couples with infertility issues and poor ovarian response.
The growing awareness and government initiatives to regulate surrogacy and increasing coverage of IVF under insurance are the other major factors that are expected to play a crucial role in the growth of the studied segment. For instance, in June 2022, the Indian state Odisha constituted a state-appropriate authority and set up the state-assisted reproductive technology and surrogacy board with the objective of regulating IVF clinics and prohibiting commercial surrogacy. With surrogacy becoming popular, the Assisted Reproductive Technology (ART) Act came as a ray of hope for infertile couples who have been battling legal, ethical, and social tussles.
Furthermore, the increasing launches of IVF facilities and new technologies across the globe to provide better ART services, including surrogacy, are also contributing to the segment growth. For instance, in November 2022, Oma Fertility partnered with agency partners to integrate technology into fertility care. Oma focuses on helping couples conceive by bringing artificial intelligence and robotics to in-house fertility treatments as well as collaborating with third parties such as surrogate agencies and egg and sperm banks.
Therefore, owing to factors such as the increasing government and hospital initiatives, rising launches of IVF facilities, and introduction of advanced technologies, the in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) segment is expected to grow over the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
North America is anticipated to witness a significant share in the surrogacy market over the forecast period owing to factors such as the rising prevalence of polycystic ovary syndrome (PCOS) among women and a constant rise in infertility cases. In addition, the presence of various leading players in this region, the growing number of single women and same-sex couples, and favorable regulatory reforms are also expected to boost the market growth.
The burden of infertility cases among the population is the key factor driving the demand for in-vitro fertilization treatments, which, in turn, is anticipated to augment the growth of the market over the forecast period. For instance, according to an article published in Advances in the Management of Infertility in February 2023, it was observed that about 12% to 15% of the reproductive-age population of women in the United States had difficulty conceiving at some point in their lives.
Additionally, the rising focus of the centers and organizations to launch various surrogacy programs is anticipated to fuel the adoption of surrogacy procedures among infertile couples in the region, which is expected to augment the market growth over the forecast period. For instance, in September 2022, Pinnacle Fertility launched Pinnacle Surrogacy, a gestational surrogacy program, to support patients undergoing treatment at a network clinic who need a gestational carrier (surrogate) to start or grow their family. It offers exceptional client services, high-quality surrogates, and expedited surrogate matching to Pinnacle network patients.
The rising adoption of various key strategic activities such as acquisitions, collaborations, and agreements among fertility clinics and hospitals is expected to increase the availability of different surrogacy procedures in the region. For instance, in August 2022, Kindbody, a US-based fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, acquired Alternative Reproductive Resources (ARR), a gestational surrogacy agency. The acquisition incorporated gestational surrogacy in-house, delivering a seamless continuum of patient care.
Furthermore, the launches of new fertility centers in the region are expected to fuel the demand for surrogacy treatment among the population, hence anticipated to contribute to the market growth. For instance, in August 2023, GoStork, United States, launched its Fertility Clinic Marketplace, a first-of-its-kind platform that takes a data-driven, customized approach to match fertility consumers with clinics based on their age, budget, personal needs, and unique fertility journey. The new Fertility Clinic Marketplace offers surrogacy agencies, egg donor agencies, and fertility financing, as well as one-on-one, personalized concierge services.
Moreover, the growing initiatives to promote the adoption of surrogacy across the region are further anticipated to augment the market growth. For instance, in May 2023, Conceive Abilities launched a Trailblazing DC Surrogate Compensation Package in the United States, in which surrogates can earn up to USD 72,000 with a limited-time bonus.
Therefore, owing to increasing infertility cases, the introduction of surrogacy programs and platforms, and the growing initiatives by companies, the market studied is anticipated to grow over the forecast period.
